Paul A. Renauer

TL;DR: This study provides a functional landscape of gliomagenesis suppressors in vivo and identifies co-occurring driver combinations such as B2m–Nf1, Mll3–N f1 and Zc3h13–Rb1, which were subsequently validated using AAV minipools.

TL;DR: High-throughput in vivo genetic screens for immunotherapy target discovery are demonstrated and DHX37 is established as a functional regulator of CD8 T cells.

TL;DR: This work leveraged CRISPR activation (CRISPRa) to directly augment the in situ expression of endogenous genes, and thereby the presentation of tumor antigens, leading to dramatic antitumor immune responses.

TL;DR: It is demonstrated that Kmt2d deficiency sensitizes tumors to ICB by augmenting tumor immunogenicity, and the power of CRISPR-GEMMs for interrogating complex molecular landscapes in immunotherapeutic contexts that preserve the native tumor microenvironment is highlighted.

TL;DR: The data suggest that tumor-intrinsic mutations in Prkar1a lead to drastic alterations in the genetic program of cancer cells, thereby remodeling the tumor microenvironment.